| __timestamp | BioCryst Pharmaceuticals, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 5114000 |
| Thursday, January 1, 2015 | 13047000 | 13403000 |
| Friday, January 1, 2016 | 11253000 | 31056000 |
| Sunday, January 1, 2017 | 13933000 | 35845000 |
| Monday, January 1, 2018 | 29514000 | 48294000 |
| Tuesday, January 1, 2019 | 37121000 | 63488000 |
| Wednesday, January 1, 2020 | 67929000 | 88208000 |
| Friday, January 1, 2021 | 118818000 | 102802000 |
| Saturday, January 1, 2022 | 159371000 | 102464000 |
| Sunday, January 1, 2023 | 213894000 | 76162000 |
| Monday, January 1, 2024 | 72977000 |
Data in motion
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, from 2014 to 2023, the Selling, General, and Administrative (SG&A) expenses of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc. have showcased intriguing trends. BioCryst Pharmaceuticals, Inc. has seen a staggering 2,768% increase in SG&A expenses, peaking at $213.9 million in 2023. In contrast, CRISPR Therapeutics AG's expenses grew by 1,389%, reaching $102.8 million in 2021 before a decline to $76.2 million in 2023. This divergence highlights BioCryst's aggressive expansion strategy, while CRISPR's recent cost-cutting measures suggest a strategic pivot. As these companies navigate the competitive biotech arena, understanding their financial strategies offers valuable insights into their future trajectories.
AbbVie Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Vertex Pharmaceuticals Incorporated or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: GSK plc vs BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and CRISPR Therapeutics AG
Comparing SG&A Expenses: Pharming Group N.V. vs CRISPR Therapeutics AG Trends and Insights
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and BioCryst Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
CRISPR Therapeutics AG or Vericel Corporation: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? HUTCHMED (China) Limited or BioCryst Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Wave Life Sciences Ltd. and BioCryst Pharmaceuticals, Inc.
Taro Pharmaceutical Industries Ltd. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?